Article ; Online: Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Multiple sclerosis (Houndmills, Basingstoke, England)
2021 Volume 28, Issue 1, Page(s) 132–138
Abstract: ... and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS ... of COVID-19 emergency on access to care for PwMS and on MS treatment practices.: Methods: Between March ... promoted an online survey covering patient access to care, management of relapses and visits, disease ...
| Abstract | Background: The spread of Coronavirus disease-19 (COVID-19) poses unique challenges in the management of people with multiple sclerosis (PwMS). Objectives: To collect data about the impact of COVID-19 emergency on access to care for PwMS and on MS treatment practices. Methods: Between March and July 2020, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) promoted an online survey covering patient access to care, management of relapses and visits, disease-modifying therapy (DMT) and experience with COVID-19. Results: Three-hundred and sixty neurologists from 52 countries (68% from Europe) completed the survey. 98% reported COVID-19-related restrictions. Telemedicine was adopted to overcome the limited access to care and was newly activated (73%) or widely implemented (17%). 70% reported changes in DMT management. Interferons and glatiramer were considered safe. Dimethyl fumarate, teriflunomide and fingolimod were considered safe except for patients developing lymphopenia. No modifications were considered for natalizumab in 64%, cladribine in 24%, anti-CD20 in 22% and alemtuzumab in 17%; 18% (for alemtuzumab and cladribine) and 43% (for anti-CD20) considered postponing treatment. Conclusion: The ECTRIMS survey highlighted the challenges in keeping standards of care in clinical practice. Telemedicine clearly needs to be implemented. Gathering data on DMT safety will remain crucial to inform treatment decisions. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | COVID-19 ; Fingolimod Hydrochloride/therapeutic use ; Humans ; Immunosuppressive Agents ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Relapsing-Remitting ; SARS-CoV-2 | |||||
| Chemical Substances | Immunosuppressive Agents ; Fingolimod Hydrochloride (G926EC510T) | |||||
| Language | English | |||||
| Publishing date | 2021-03-25 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 1290669-4 | |||||
| ISSN | 1477-0970 ; 1352-4585 | |||||
| ISSN (online) | 1477-0970 | |||||
| ISSN | 1352-4585 | |||||
| DOI | 10.1177/13524585211005339 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 4428: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.